Valuation OSE Immunotherapeutics Deutsche Boerse AG
Stocks
6OP
FR0012127173
Biotechnology & Medical Research
|
Market Closed -
Deutsche Boerse AG
02:02:47 2026-09-01 EDT
|
5-day change | 1st Jan Change | ||
| 3.156 EUR | +0.96% |
|
+0.57% | -39.77% |
| 08-19 | Moderna-Merck melanoma vaccine leads race for first therapeutic cancer vaccine | RE |
| 06-11 | OSE Immunotherapeutics Recovers Following Oddo BHF Endorsement |  |
Company Valuation: OSE Immunotherapeutics
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 187.7 | 123.4 | 80.55 | 156.8 | 115.5 | 75.17 | - | - |
| Change | - | -34.26% | -34.73% | 94.71% | -26.37% | -34.9% | - | - |
| Enterprise Value (EV) 1 | 186.5 | 138.1 | 100.4 | 186.2 | 134.2 | 116 | 138.3 | 160.2 |
| Change | - | -25.96% | -27.29% | 85.45% | -27.93% | -13.6% | 19.23% | 15.86% |
| P/E | -11.1x | -6.95x | -3.63x | 4.84x | -3.05x | -2.46x | -2.81x | 1.33x |
| PBR | - | 3.79x | 3.64x | 2.45x | 4.13x | -11x | -1.37x | -0.85x |
| PEG | - | -2.15x | -0.2x | -0x | 0x | 0.1x | 0.2x | -0x |
| Capitalization / Revenue | 7.14x | 6.74x | 36.2x | 1.88x | 44.1x | 15.3x | 7.14x | 0.76x |
| EV / Revenue | 7.09x | 7.55x | 45.1x | 2.23x | 51.2x | 23.7x | 13.1x | 1.61x |
| EV / EBITDA | -13.1x | -8.83x | -4.92x | 3.78x | -3.92x | -4.2x | -5.57x | 2.38x |
| EV / EBIT | -11.2x | -7.51x | -4.37x | 4.26x | -3.58x | -3.92x | -5.07x | 2.49x |
| EV / FCF | -18x | -7.45x | -5.08x | 3.85x | -3.93x | -3.61x | -3.19x | -5.52x |
| FCF Yield | -5.57% | -13.4% | -19.7% | 26% | -25.4% | -27.7% | -31.4% | -18.1% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -0.93 | -0.96 | -1.18 | 1.48 | -1.69 | -1.301 | -1.136 | 2.398 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 26.31 | 18.3 | 2.227 | 83.44 | 2.619 | 4.9 | 10.53 | 99.47 |
| EBITDA 1 | -14.29 | -15.65 | -20.41 | 49.26 | -34.24 | -27.62 | -24.81 | 67.27 |
| EBIT 1 | -16.62 | -18.39 | -22.98 | 43.74 | -37.49 | -29.58 | -27.25 | 64.4 |
| Net income 1 | -16.85 | -17.76 | -23 | 37.44 | -37.69 | -30.59 | -21.47 | 64.4 |
| Net Debt 1 | -1.167 | 14.7 | 19.87 | 29.39 | 18.74 | 40.79 | 63.08 | 85.01 |
| Reference price 2 | 10.280 | 6.675 | 4.280 | 7.170 | 5.150 | 3.196 | 3.196 | 3.196 |
| Nbr of stocks (in thousands) | 18,259 | 18,488 | 18,819 | 21,873 | 22,421 | 23,520 | - | - |
| Announcement Date | 3/30/22 | 4/27/23 | 3/27/24 | 3/26/25 | 6/5/26 | - | - | - |
1EUR in Million2EUR
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 33.86x | 6.04x | 17.97x | 0.95% | 49.81B | |
| -21.01x | 245.16x | -22.36x | -.--% | 44.06B | |
| 33.64x | 3.26x | 14.08x | -.--% | 42.99B | |
| 47.1x | 5.45x | 29.8x | -.--% | 40.88B | |
| 28.69x | 8.67x | 21.92x | 0.4% | 33.11B | |
| 33.78x | 5.53x | 25.14x | -.--% | 16.58B | |
| 24.18x | 2.1x | 9.1x | 1.11% | 14.63B | |
| 77.11x | 4.06x | 15.74x | -.--% | 13.76B | |
| Average | 32.17x | 35.03x | 13.92x | 0.31% | 31.98B | |
| Weighted average by Cap. | 27.59x | 46.64x | 12.61x | 0.3% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- OSE Stock
- 6OP Stock
- Valuation OSE Immunotherapeutics
Select your edition
All financial news and data tailored to specific country editions
